Chimerix antiviral drug fails in late-stage study

(Reuters) – Chimerix Inc said its oral antiviral drug did not significantly reduce a certain kind of infection in stem cell transplant patients in a late-stage study, sending its shares down 72 percent in premarket trading. Patients taking the drug, brincidofovir, did not experience significant reduction in cytomegalovirus (CMV) infection through week 24 after transplant. CMV is a member of the herpes virus family and remains a significant cause of viral infections in transplant recipients. …
Sexual Health News Headlines – Yahoo! News